Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- AXSM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Axsome Therapeutics, Mental Health America partner for Mental Health Month
- Axsome Therapeutics price target raised to $193 from $190 at RBC Capital
- Positive Outlook on Axsome Therapeutics Driven by Auvelity’s Strong Commercial Performance
- Positive Outlook on Axsome Therapeutics’ AXS-12 for Narcolepsy Treatment Amid Promising Phase III Results